Skip to main content
. 2023 Sep 1;12:29. doi: 10.1186/s13619-023-00172-9

Fig. 1.

Fig. 1

Schematic of ECM-degrading cell therapy applied to fibrosis. During fibrosis, the ECM is excessively secreted and deposited. Delivery of ECM-degrading cells to fibrotic organs or tissues can degrade the deposited ECM mainly by secreting MMPs, which are expected to  reduce excessive fibrosis